Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
Dasatinib Tablets (RLD Sprycel) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
Lutio has the potential to offer significant cost savings when available to UK patients.
Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.
Subscribe To Our Newsletter & Stay Updated